8-K: Forte Biosciences Reports First Quarter 2024 Results and Provides Business Update

Forte Biosciences announced its first quarter 2024 financial results and provided an update on the progress of its lead drug candidate, FB102.

Summary

• Forte Biosciences reported a net loss of $7.42 million, or $0.16 per share, for the first quarter of 2024, compared to a net loss of $6.75 million, or $0.32 per share, for the same period in 2023.
• Research and development expenses decreased to $4.4 million from $4.8 million year-over-year, primarily due to lower manufacturing costs, partially offset by increased clinical trial expenses and payroll.
• General and administrative expenses increased to $3.5 million from $2.1 million year-over-year, mainly due to higher legal and professional fees.
• The company ended the quarter with $30.4 million in cash and cash equivalents.
• Forte's lead drug candidate, FB102, has completed the single ascending dose portion of its Phase 1 trial and is expected to complete the multiple ascending dose cohorts around mid-year.
• Patient-based studies for FB102 are expected to begin before the end of the year.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical progress and financial challenges. The progress of FB102 and its potential are encouraging, but the increased expenses and net loss are concerning. The company's cash position is still strong, but the need for additional capital is a risk.

Positives

• The company has made excellent progress with the FB102 program, completing the single ascending dose portion of the Phase 1 trial.
• FB102 has demonstrated a good safety profile to date, including in the multiple ascending dose cohorts.
• The company has a strong cash position of $30.4 million.
• Net losses per share improved year-over-year, from ($0.32) to ($0.16).
• Preclinical data for FB102 shows promise across multiple autoimmune indications.

Negatives

• The company experienced a net loss of $7.42 million for the quarter.
• General and administrative expenses increased significantly, primarily due to higher legal and professional fees.
• The company's cash position decreased from $37.1 million at the end of 2023 to $30.4 million at the end of the first quarter of 2024.

Risks

• The company's ability to obtain sufficient additional capital to continue to advance FB102 is a risk.
• There are uncertainties associated with the clinical development and regulatory approval of FB102, including potential delays in clinical trials.
• The results from preclinical and early clinical studies may not be predictive of future results.
• There is a risk associated with the failure to realize any value from FB102 due to the inherent risks, expense, and difficulties involved in bringing product candidates to market.

Future Outlook

Forte expects to complete the multiple ascending dose cohorts of the FB102 Phase 1 trial around mid-year and initiate patient-based studies before the end of the year. The company believes FB102 has significant potential across various autoimmune diseases.

Management Comments

• Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences, stated that Forte continues to make excellent progress with FB102.
• Paul Wagner also mentioned that the data to date supports the significant potential for FB102 across a variety of autoimmune and autoimmune-related diseases.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on autoimmune and autoimmune-related diseases. The market for vitiligo and alopecia areata treatments is projected to reach $5.8 billion by 2026, indicating a significant opportunity for Forte's FB102.

Comparison to Industry Standards

• Forte's FB102 is an anti-CD122 antibody, a different mechanism of action compared to JAK inhibitors, which have faced regulatory scrutiny.
• Preclinical data for FB102 in a humanized mouse model of acute GVHD showed a 90% survival rate, compared to 60% for Ruxolitinib, a JAK inhibitor, and 0% for the control group.
• Other companies like Incyte with Ruxolitinib and Equillium/Ono with Itolizumab are also developing treatments for GVHD, but FB102's preclinical results suggest a potentially superior efficacy.
• The company is targeting a market with a significant unmet need for safe and effective therapies for autoimmune diseases, particularly vitiligo and alopecia areata, where JAK inhibitors have shown limitations.

Related Party Transactions

• Research and development expenses included $29 thousand of related party transactions for the three months ending March 31, 2024.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the progress of FB102.
• Employees are impacted by the company's operational and financial performance.
• Customers (potential patients) may benefit from the development of FB102 if it proves to be a safe and effective treatment.
• Creditors are impacted by the company's financial health and ability to repay debts.
• Suppliers are impacted by the company's operational and financial performance.

Next Steps

• Complete the multiple ascending dose cohorts of the FB102 Phase 1 trial around mid-year.
• Initiate patient-based studies for FB102 before the end of the year.
• Continue to advance the FB102 program and explore its potential across various autoimmune diseases.

Key Dates

Keywords

FB102, autoimmune diseases, clinical trials, biopharmaceutical, research and development, graft-versus-host disease, vitiligo, alopecia areata, anti-CD122 antibody, Phase 1 trial